BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 12942787)

  • 21. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
    Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
    Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
    Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
    Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.
    Sato T; Tateda K; Kimura S; Iwata M; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1588-93. PubMed ID: 21220534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
    Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
    APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002).
    Inoue M; Kaneko K; Akizawa K; Fujita S; Kaku M; Igari J; Yamaguchi K; Kohno S; Yamanaka K; Iinuma Y; Murase M; Yokoyama T; Asari S; Hirakata Y
    J Infect Chemother; 2006 Feb; 12(1):9-21. PubMed ID: 16506084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study on azithromycin in 10% fine granules and 100mg capsules in the field of pediatrics].
    Motohiro T; Nagai K; Yamada S; Tsumura N; Yamada T; Oda K; Sakata Y; Kato H; Gakuen Y; Imai S; Sasaki H; Morita J; Ikezawa S; Matsuo Y; Yamashita Y; Aramaki M; Araki H; Yasuoka C; Hayashi M; Ono E; Hashimoto N; Kubota K; Kawakami A; Toyoda A; Wada M
    Jpn J Antibiot; 1997 Mar; 50(3):272-97. PubMed ID: 9634360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
    Beekmann SE; Heilmann KP; Richter SS; García-de-Lomas J; Doern GV;
    Int J Antimicrob Agents; 2005 Feb; 25(2):148-56. PubMed ID: 15664485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.
    Cizman M; Beović B; Seme K; Paragi M; Strumbelj I; Müller-Premru M; Cad-Pecar S; Pokorn M
    Int J Antimicrob Agents; 2006 Dec; 28(6):537-42. PubMed ID: 17101264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.